CANTARGIA AB | MedPath

Robust Pipeline of 200+ Therapies Targets Colorectal Cancer Treatment Landscape

2 months ago

• DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies. • Key drug candidates include XL092 (Exelixis), Adagrasib (Mirati Therapeutics), Olaparib (Merck/AstraZeneca), and novel approaches like LYL845, an autologous tumor-infiltrating lymphocyte therapy from Lyell Immunopharma. • The metastatic colorectal cancer segment shows particular promise with 150+ companies advancing 180+ pipeline therapies, including innovative treatments targeting specific mutations and immune pathways.

Cantargia's Novel Anti-IL1RAP Antibody-Drug Conjugate Shows Promising Preclinical Efficacy Against Cancer

2 months ago

• Cantargia's anti-IL1RAP antibody-drug conjugate demonstrated potent anti-tumor activity across different IL1RAP expression levels in preclinical models, with a single dose achieving 100% survival in high-expressing tumors. • The ADC targets IL1RAP, a protein overexpressed in many tumor cells and their microenvironment, providing a dual-targeting approach that could potentially improve cancer treatment outcomes. • Preclinical safety data showed the ADC was well-tolerated with no significant changes in body weight, liver and kidney enzyme levels, or histological abnormalities in assessed organs.

Cantargia Initiates First Clinical Trial of Nadunolimab for AML and MDS Treatment

2 months ago

• Swedish biotech Cantargia has enrolled the first patient in a Phase Ib/IIa trial investigating nadunolimab in combination with standard chemotherapy for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). • The US Department of Defense-funded study aims to enroll 40 patients and will assess safety, dosing recommendations, and efficacy measures including overall response rates and duration of response, with full recruitment expected by 2027. • This marks nadunolimab's first application in hematological malignancies, building on promising results in solid tumors and leveraging the discovery that leukemia stem cells express IL1RAP, the antibody's target protein.

Cantargia's CAN10 Shows Promising Phase 1 Results for Hidradenitis Suppurativa Treatment

3 months ago

• Cantargia reports positive pharmacokinetic data from the first multiple dose cohort of CAN10, supporting potential monthly dosing which would offer competitive advantages in hidradenitis suppurativa treatment. • FDA has provided favorable feedback on Cantargia's proposed Phase 2 study design for CAN10 in hidradenitis suppurativa, with the company on track for IND submission in the second half of 2025. • Clinical experts from the US and Europe have strongly endorsed CAN10's development for hidradenitis suppurativa, citing significant unmet medical needs despite recent treatment approvals.

Myocardial Infarction Therapeutics Pipeline Shows Promise with Over 45 Companies Involved

4 months ago

• The myocardial infarction therapeutics pipeline is robust, featuring over 45 companies developing more than 50 potential drugs. • Key companies like Boehringer Ingelheim and Idorsia Pharmaceuticals are advancing novel therapies to improve outcomes post-myocardial infarction. • Several promising therapies, including Selatogrel and FDY-5301, are in Phase III trials, showing potential for significant advancements. • Recent clinical trial activities, such as the commencement of the PERFECT study and completion of enrollment in the Iocyte AMI-3 trial, highlight ongoing research efforts.